nasdaq:cprx
|
606814
|
Mar 24th, 2024 12:00AM
|
Catalyst Pharmaceuticals, Inc.
|
9.1K
|
143.00
|
Open
|
|
Mar 24th, 2024 12:24AM
|
Mar 24th, 2024 12:24AM
|
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
|
Open
|
Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease
|
Open
|
355 Alhambra Circle
|
Coral Gables
|
Florida
|
US
|
33134
|
|
Catalyst Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:cprx
|
606814
|
Mar 23rd, 2024 12:00AM
|
Catalyst Pharmaceuticals, Inc.
|
9.1K
|
143.00
|
Open
|
|
Mar 22nd, 2024 11:21PM
|
Mar 23rd, 2024 06:35PM
|
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
|
Open
|
Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease
|
Open
|
355 Alhambra Circle
|
Coral Gables
|
Florida
|
US
|
33134
|
|
Catalyst Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:cprx
|
606814
|
Mar 22nd, 2024 12:00AM
|
Catalyst Pharmaceuticals, Inc.
|
9.1K
|
143.00
|
Open
|
|
Mar 21st, 2024 11:16PM
|
Mar 22nd, 2024 06:23PM
|
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
|
Open
|
Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease
|
Open
|
355 Alhambra Circle
|
Coral Gables
|
Florida
|
US
|
33134
|
|
Catalyst Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:cprx
|
606814
|
Mar 21st, 2024 12:00AM
|
Catalyst Pharmaceuticals, Inc.
|
9.1K
|
143.00
|
Open
|
|
Mar 20th, 2024 11:28PM
|
Mar 21st, 2024 05:07PM
|
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
|
Open
|
Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease
|
Open
|
355 Alhambra Circle
|
Coral Gables
|
Florida
|
US
|
33134
|
|
Catalyst Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:cprx
|
606814
|
Mar 20th, 2024 12:00AM
|
Catalyst Pharmaceuticals, Inc.
|
9.0K
|
143.00
|
Open
|
|
Mar 19th, 2024 11:37PM
|
Mar 20th, 2024 07:07PM
|
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
|
Open
|
Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease
|
Open
|
355 Alhambra Circle
|
Coral Gables
|
Florida
|
US
|
33134
|
|
Catalyst Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:cprx
|
606814
|
Mar 19th, 2024 12:00AM
|
Catalyst Pharmaceuticals, Inc.
|
9.0K
|
143.00
|
Open
|
|
Mar 18th, 2024 11:03PM
|
Mar 19th, 2024 05:39PM
|
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
|
Open
|
Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease
|
Open
|
355 Alhambra Circle
|
Coral Gables
|
Florida
|
US
|
33134
|
|
Catalyst Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:cprx
|
606814
|
Mar 18th, 2024 12:00AM
|
Catalyst Pharmaceuticals, Inc.
|
9.0K
|
143.00
|
Open
|
|
Mar 17th, 2024 11:25PM
|
Mar 18th, 2024 06:51PM
|
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
|
Open
|
Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease
|
Open
|
355 Alhambra Circle
|
Coral Gables
|
Florida
|
US
|
33134
|
|
Catalyst Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:cprx
|
606814
|
Mar 17th, 2024 12:00AM
|
Catalyst Pharmaceuticals, Inc.
|
9.0K
|
143.00
|
Open
|
|
Mar 17th, 2024 12:19AM
|
Mar 17th, 2024 12:19AM
|
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
|
Open
|
Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease
|
Open
|
355 Alhambra Circle
|
Coral Gables
|
Florida
|
US
|
33134
|
|
Catalyst Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:cprx
|
606814
|
Mar 16th, 2024 12:00AM
|
Catalyst Pharmaceuticals, Inc.
|
9.0K
|
143.00
|
Open
|
|
Mar 15th, 2024 10:55PM
|
Mar 16th, 2024 06:39PM
|
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
|
Open
|
Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease
|
Open
|
355 Alhambra Circle
|
Coral Gables
|
Florida
|
US
|
33134
|
|
Catalyst Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:cprx
|
606814
|
Mar 15th, 2024 12:00AM
|
Catalyst Pharmaceuticals, Inc.
|
9.0K
|
143.00
|
Open
|
|
Mar 14th, 2024 11:54PM
|
Mar 15th, 2024 08:28AM
|
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
|
Open
|
Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease
|
Open
|
355 Alhambra Circle
|
Coral Gables
|
Florida
|
US
|
33134
|
|
Catalyst Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|